MyD88-dependent immunity to a natural model of vaccinia virus infection does not involve toll-like receptor 2

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3557-3567

  Davies, Michael L ^a   Sei, Janet J ^a   Siciliano, Nicholas A ^b   Xu, Ren Huan ^c   Roscoe, Felicia ^c   Sigal, Luis J ^c   Eisenlohr, Laurence C ^b   Norbury, Christopher C ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; INTERLEUKIN 18; INTERLEUKIN 1BETA; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IN VITRO STUDY; INNATE IMMUNITY; INTRACELLULAR SIGNALING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VACCINIA; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS REPLICATION;

ADAPTIVE IMMUNITY; ANIMALS; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; TOLL-LIKE RECEPTOR 2; VACCINIA; VACCINIA VIRUS;

EID: 84894535025     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02776-13     Document Type: Article

References (79)

1. Kang JY, Lee JO. 2011. Structural biology of the Toll-like receptor family. Annu. Rev. Biochem. 80:917-941. http://dx.doi.org/10.1146/annurev-biochem-052909-141507.
2. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11:373-384. http://dx.doi.org/10.1038/ni.1863.
3. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P, Zychlinsky A. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285: 736-739. http://dx.doi.org/10.1126/science.285.5428.736.
4. Calich VL, Pina A, Felonato M, Bernardino S, Costa TA, Loures FV. 2008. Toll-like receptors and fungal infections: the role of TLR2, TLR4 and MyD88 in paracoccidioidomycosis. FEMS Immunol. Med. Microbiol. 53: 1-7. http://dx.doi.org/10.1111/j.1574-695X.2008.00378.x.
5. Carrera-Silva EA, Guinazu N, Pellegrini A, Cano RC, Arocena A, Aoki MP, Gea S. 2010. Importance of TLR2 on hepatic immune and nonimmune cells to attenuate the strong inflammatory liver response during Trypanosoma cruzi acute infection. PLoS Negl. Trop. Dis. 4:e863. http://dx.doi.org/10.1371/journal.pntd.0000863.
6. Zhang M, Gao Y, Du X, Zhang D, Ji M, Wu G. 2011. Toll-like receptor (TLR) 2 and TLR4 deficiencies exert differential in vivo effects against Schistosoma japonicum. Parasite Immunol. 33:199-209. http://dx.doi.org/10.1111/j.1365-3024.2010.01265.x.
7. Love W, Dobbs N, Tabor L, Simecka JW. 2010. Toll-like receptor 2 (TLR2) plays a major role in innate resistance in the lung against murine Mycoplasma. PLoS One 5:e10739. http://dx.doi.org/10.1371/journal.pone.0010739.
8. Mele T, Madrenas J. 2010. TLR2 signalling: at the crossroads of commensalism, invasive infections and toxic shock syndrome by Staphylococcus aureus. Int. J. Biochem. Cell Biol. 42:1066-1071. http://dx.doi.org/10.1016/j.biocel.2010.03.021.
9. Zamboni DS, Campos MA, Torrecilhas AC, Kiss K, Samuel JE, Golenbock DT, Lauw FN, Roy CR, Almeida IC, Gazzinelli RT. 2004. Stimulation of toll-like receptor 2 by Coxiella burnetii is required for macrophage production of pro-inflammatory cytokines and resistance to infection. J. Biol. Chem. 279:54405-54415. http://dx.doi.org/10.1074/jbc.M410340200.
10. Lima GK, Zolini GP, Mansur DS, Freire Lima BH, Wischhoff U, Astigarraga RG, Dias MF, das Gracas Almeida Silva M, Bela SR, do Valle Antonelli LR, Arantes RM, Gazzinelli RT, Bafica A, Kroon EG, Campos MA. 2010. Toll-like receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia are critical to viral control during herpes simplex virus 1 infection. Am. J. Pathol. 177:2433-2445. http://dx.doi.org/10.2353/ajpath.2010.100121.
11. Cuevas CD, Lavanya M, Wang E, Ross SR. 2011. Junin virus infects mouse cells and induces innate immune responses. J. Virol. 85:11058-11068. http://dx.doi.org/10.1128/JVI.05304-11.
12. Piccinini AM, Midwood KS. 2010. DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010:672395. http://dx.doi.org/10.1155/2010/672395.
13. Erridge C. 2010. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J. Leukoc. Biol. 87:989-999. http://dx.doi.org/10.1189/jlb.1209775.
14. Zähringer U, Lindner B, Inamura S, Heine H, Alexander C. 2008. TLR2-promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 213:205-224. http://dx.doi.org/10.1016/j.imbio.2008.02.005.
15. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327:291-295. http://dx.doi.org/10.1126/science.1183021.
16. Dietrich N, Lienenklaus S, Weiss S, Gekara NO. 2010. Murine toll-like receptor 2 activation induces type I interferon responses from endolysosomal compartments. PLoS One 5:e10250. http://dx.doi.org/10.1371/journal.pone.0010250.
17. Barbalat R, Lau L, Locksley RM, Barton GM. 2009. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat. Immunol. 10:1200-1207. http://dx.doi.org/10.1038/ni.1792.
18. Aubry C, Corr SC, Wienerroither S, Goulard C, Jones R, Jamieson AM, Decker T, O'Neill LA, Dussurget O, Cossart P. 2012. Both TLR2 and TRIF contribute to interferon-beta production during Listeria infection. PLoS One 7:e33299. http://dx.doi.org/10.1371/journal.pone.0033299.
19. Kennedy RB, Ovsyannikova IG, Jacobson RM, Poland GA. 2009. The immunology of smallpox vaccines. Curr. Opin. Immunol. 21:314-320. http://dx.doi.org/10.1016/j.coi.2009.04.004.
20. Lousberg EL, Diener KR, Brown MP, Hayball JD. 2011. Innate immune recognition of poxviral vaccine vectors. Expert Rev. Vaccines 10:1435-1449. http://dx.doi.org/10.1586/erv.11.121.
21. Senkevich TG, Bugert JJ, Sisler JR, Koonin EV, Moss B. 1996. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 273:813-816. http://dx.doi.org/10.1126/science.273.5276.813.
22. Tscharke DC, Smith GL. 1999. A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J. Gen. Virol. 80:2751-2755.
23. Tscharke DC, Reading PC, Smith GL. 2002. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J. Gen. Virol. 83:1977-1986.
24. Delaloye J, Roger T, Steiner-Tardivel QG, Le Roy D, Knaup Reymond M, Akira S, Petrilli V, Gomez CE, Perdiguero B, Tschopp J, Pantaleo G, Esteban M, Calandra T. 2009. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog. 5:e1000480. http://dx.doi.org/10.1371/journal.ppat.1000480.
25. Zhu J, Martinez J, Huang X, Yang Y. 2007. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109:619-625. http://dx.doi.org/10.1182/blood-2006-06-027136.
26. Sutherland DB, Ranasinghe C, Regner M, Phipps S, Matthaei KI, Day SL, Ramshaw IA. 2011. Evaluating vaccinia virus cytokine co-expression in TLR GKO mice. Immunol. Cell Biol. 89:706-715. http://dx.doi.org/10.1038/icb.2010.157.
27. Quigley M, Martinez J, Huang X, Yang Y. 2009. A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection. Blood 113:2256-2264. http://dx.doi.org/10.1182/blood-2008-03-148809.
28. Zhao Y, De Trez C, Flynn R, Ware CF, Croft M, Salek-Ardakani S. 2009. The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus. J. Immunol. 182:6278-6286. http://dx.doi.org/10.4049/jimmunol.0803682.
29. Collazo CM, Sher A, Meierovics AI, Elkins KL. 2006. Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication. Microbes Infect. 8:779-790. http://dx.doi.org/10.1016/j.micinf.2005.09.014.
30. Malik M, Bakshi CS, Sahay B, Shah A, Lotz SA, Sellati TJ. 2006. Toll-like receptor 2 is required for control of pulmonary infection with Francisella tularensis. Infect. Immun. 74:3657-3662. http://dx.doi.org/10.1128/IAI.02030-05.
31. Miller LS, O'Connell RM, Gutierrez MA, Pietras EM, Shahangian A, Gross CE, Thirumala A, Cheung AL, Cheng G, Modlin RL. 2006. MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity 24:79-91. http://dx.doi.org/10.1016/j.immuni.2005.11.011.
32. Miller LS. 2008. Toll-like receptors in skin. Adv. Dermatol. 24:71-87. http://dx.doi.org/10.1016/j.yadr.2008.09.004.
33. O'Gorman WE, Sampath P, Simonds EF, Sikorski R, O'Malley M, Krutzik PO, Chen H, Panchanathan V, Chaudhri G, Karupiah G, Lewis DB, Thorne SH, Nolan GP. 2010. Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses. Cell Host Microbe 8:174-185. http://dx.doi.org/10.1016/j.chom.2010.07.008.
34. Antón LC, Schubert U, Bacik I, Princiotta MF, Wearsch PA, Gibbs J, Day PM, Realini C, Rechsteiner MC, Bennink JR, Yewdell JW. 1999. Intracellular localization of proteasomal degradation of a viral antigen. J. Cell Biol. 146:113-124. http://dx.doi.org/10.1083/jcb.146.1.113.
35. Moutaftsi M, Bui HH, Peters B, Sidney J, Salek-Ardakani S, Oseroff C, Pasquetto V, Crotty S, Croft M, Lefkowitz EJ, Grey H, Sette A. 2007. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+T cell responses. J. Immunol. 178:6814-6820.
36. Xu RH, Rubio D, Roscoe F, Krouse TE, Truckenmiller ME, Norbury CC, Hudson PN, Damon IK, Alcami A, Sigal LJ. 2012. Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver. PLoS Pathog. 8:e1002475. http://dx.doi.org/10.1371/journal.ppat.1002475.
37. Rubio D, Xu RH, Remakus S, Krouse TE, Truckenmiller ME, Thapa RJ, Balachandran S, Alcami A, Norbury CC, Sigal LJ. 2013. Crosstalk between the type 1 interferon and nuclear factor kappa B pathways confers resistance to a lethal virus infection. Cell Host Microbe 13:701-710. http://dx.doi.org/10.1016/j.chom.2013.04.015.
38. Fischer MA, Davies ML, Reider IE, Heipertz EL, Epler MR, Sei JJ, Ingersoll MA, Rooijen NV, Randolph GJ, Norbury CC. 2011. CD11b(+), Ly6G(+) cells produce type I interferon and exhibit tissue protective properties following peripheral virus infection. PLoS Pathog. 7:e1002374. http://dx.doi.org/10.1371/journal.ppat.1002374.
39. Iborra S, Izquierdo HM, Martinez-Lopez M, Blanco-Menendez N, Reis e Sousa C, Sancho D. 2012. The DC receptor DNGR-1 mediates crosspriming of CTLs during vaccinia virus infection in mice. J. Clin. Invest. 122:1628-1643. http://dx.doi.org/10.1172/JCI60660.
40. Tian T, Dubin K, Jin Q, Qureshi A, King SL, Liu L, Jiang X, Murphy GF, Kupper TS, Fuhlbrigge RC. 2012. Disruption of TNF-alpha/TNFR1 function in resident skin cells impairs host immune response against cutaneous vaccinia virus infection. J. Invest. Dermatol. 132:1425-1434. http://dx.doi.org/10.1038/jid.2011.489.
41. Hutt LM. 1975. The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cellassociated and cell-free virus. J. Hyg. (Lond.) 74:301-314.
42. Xu R, Johnson AJ, Liggitt D, Bevan MJ. 2004. Cellular and humoral immunity against vaccinia virus infection of mice. J. Immunol. 172:6265-6271.
43. Buller RML, Palumbo GJ. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122.
44. Chapman JL, Nichols DK, Martinez MJ, Raymond JW. 2010. Animal models of orthopoxvirus infection. Vet. Pathol. 47:852-870. http://dx.doi.org/10.1177/0300985810378649.
45. Reading PC, Moore JB, Smith GL. 2003. Steroid hormone synthesis by vaccinia virus suppresses the inflammatory response to infection. J. Exp. Med. 197:1269-1278. http://dx.doi.org/10.1084/jem.20022201.
46. Remakus S, Sigal LJ. 2011. Gamma interferon and perforin control the strength, but not the hierarchy, of immunodominance of an antiviral CD8+ T cell response. J. Virol. 85:12578-12584. http://dx.doi.org/10.1128/JVI.05334-11.
47. Zhao Y, Adams YF, Croft M. 2011. Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-beta. Viral Immunol. 24:387-396. http://dx.doi.org/10.1089/vim.2011.0020.
48. Esteban DJ, Buller RM. 2005. Ectromelia virus: the causative agent of mousepox. J. Gen. Virol. 86:2645-2659. http://dx.doi.org/10.1099/vir.0.81090-0.
49. Hickman HD, Reynoso GV, Ngudiankama BF, Rubin EJ, Magadan JG, Cush SS, Gibbs J, Molon B, Bronte V, Bennink JR, Yewdell JW. 2013. Anatomically restricted synergistic antiviral activities of innate and adaptive immune cells in the skin. Cell Host Microbe 13:155-168. http://dx.doi.org/10.1016/j.chom.2013.01.004.
50. Crane MJ, Gaddi PJ, Salazar-Mather TP. 2012. UNC93B1 mediates innate inflammation and antiviral defense in the liver during acute murine cytomegalovirus infection. PLoS One 7:e39161. http://dx.doi.org/10.1371/journal.pone.0039161.
51. Oliveira-Nascimento L, Massari P, Wetzler LM. 2012. The role of TLR2 in infection and immunity. Front. Immunol. 3:79. http://dx.doi.org/10.3389/fimmu.2012.00079.
52. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter Meulen V, Schneider-Schaulies S. 2002. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J. Virol. 76:8729-8736. http://dx.doi.org/10.1128/JVI.76.17.8729-8736.2002.
53. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. 2004. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513-1524. http://dx.doi.org/10.1053/j.gastro.2004.08.067.
54. Ariza ME, Glaser R, Kaumaya PT, Jones C, Williams MV. 2009. The EBV-encoded dUTPase activates NF-kappa B through the TLR2 and MyD88-dependent signaling pathway. J. Immunol. 182:851-859.
55. Leoni V, Gianni T, Salvioli S, Campadelli-Fiume G. 2012. Herpes simplex virus glycoproteins gH/gL and gB bind Toll-like receptor 2, and soluble gH/gL is sufficient to activate NF-κB. J. Virol. 86:6555-6562. http://dx.doi.org/10.1128/JVI.00295-12.
56. Ovsyannikova IG, Haralambieva IH, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA. 2011. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity. Hum. Genet. 130:547-561. http://dx.doi.org/10.1007/s00439-011-0977-x.
57. Nischalke HD, Coenen M, Berger C, Aldenhoff K, Muller T, Berg T, Kramer B, Korner C, Odenthal M, Schulze F, Grunhage F, Nattermann J, Sauerbruch T, Spengler U. 2012. The toll-like receptor 2 (TLR2)-196 to-174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int. J. Cancer 130:1470-1475. http://dx.doi.org/10.1002/ijc.26143.
58. Sarangi PP, Kim B, Kurt-Jones E, Rouse BT. 2007. Innate recognition network driving herpes simplex virus-induced corneal immunopathology: role of the toll pathway in early inflammatory events in stromal keratitis. J. Virol. 81:11128-11138. http://dx.doi.org/10.1128/JVI.01008-07.
59. Wang JP, Bowen GN, Zhou S, Cerny A, Zacharia A, Knipe DM, Finberg RW, Kurt-Jones EA. 2012. Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J. Virol. 86: 2273-2281. http://dx.doi.org/10.1128/JVI.06010-11.
60. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW. 2006. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J. Virol. 80:4286-4291. http://dx.doi.org/10.1128/JVI.80.9.4286-4291.2006.
61. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, Bates EE, Kastner P, Chan S, Akira S, Vicari A, Biron CA, Trinchieri G, Briere F. 2005. MyD88-dependent and-independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J. Immunol. 175:6723-6732.
62. Hokeness-Antonelli KL, Crane MJ, Dragoi AM, Chu WM, Salazar-Mather TP. 2007. IFN-alphabeta-mediated inflammatory responses and antiviral defense in liver is TLR9-independent but MyD88-dependent during murine cytomegalovirus infection. J. Immunol. 179:6176-6183.
63. Martinez J, Huang X, Yang Y. 2010. Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog. 6:e1000811. http://dx.doi.org/10.1371/journal.ppat.1000811.
64. Waibler Z, Anzaghe M, Frenz T, Schwantes A, Pohlmann C, Ludwig H, Palomo-Otero M, Alcami A, Sutter G, Kalinke U. 2009. Vaccinia virusmediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83:1563-1571. http://dx.doi.org/10.1128/JVI.01617-08.
65. Gherardi MM, Ramirez JC, Esteban M. 2003. IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J. Gen. Virol. 84:1961-1972. http://dx.doi.org/10.1099/vir.0.19120-0.
66. Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Ohashi K, Ikeda M, Kurimoto M. 1999. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 11:593-599. http://dx.doi.org/10.1006/cyto.1998.0453.
67. Perdiguero B, Esteban M. 2009. The interferon system and vaccinia virus evasion mechanisms. J. Interferon Cytokine Res. 29:581-598. http://dx.doi.org/10.1089/jir.2009.0073.
68. Alcamí A, Smith GL. 1996. A mechanism for the inhibition of fever by a virus. Proc. Natl. Acad. Sci. U.S.A. 93:11029-11034. http://dx.doi.org/10.1073/pnas.93.20.11029.
69. Tian T, Liu L, Freyschmidt EJ, Murphy GF, Kupper TS, Fuhlbrigge RC. 2009. Overexpression of IL-1alpha in skin differentially modulates the immune response to scarification with vaccinia virus. J. Invest. Dermatol. 129:70-78. http://dx.doi.org/10.1038/jid.2008.191.
70. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, Klemenz R, Nakae S, Adler H, Merkler D, Lohning M, Pinschewer DD. 2012. The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses. Science 335:984-989. http://dx.doi.org/10.1126/science.1215418.
71. Michaud F, Coulombe F, Gaudreault E, Kriz J, Gosselin J. 2010. Involvement of TLR2 in recognition of acute gammaherpesvirus-68 infection. PLoS One 5:e13742. http://dx.doi.org/10.1371/journal.pone.0013742.
72. Zucchini N, Bessou G, Traub S, Robbins SH, Uematsu S, Akira S, Alexopoulou L, Dalod M. 2008. Cutting edge: overlapping functions of TLR7 and TLR9 for innate defense against a herpesvirus infection. J. Immunol. 180:5799-5803.
73. Kaminski MM, Ohnemus A, Cornitescu M, Staeheli P. 2012. Plasmacytoid dendritic cells and Toll-like receptor 7-dependent signalling promote efficient protection of mice against highly virulent influenza A virus. J. Gen. Virol. 93:555-559. http://dx.doi.org/10.1099/vir.0.039065-0.
74. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206:79-87. http://dx.doi.org/10.1084/jem.20081667.
75. Jung A, Kato H, Kumagai Y, Kumar H, Kawai T, Takeuchi O, Akira S. 2008. Lymphocytoid choriomeningitis virus activates plasmacytoid dendritic cells and induces a cytotoxic T-cell response via MyD88. J. Virol. 82:196-206. http://dx.doi.org/10.1128/JVI.01640-07.
76. Zhou S, Kurt-Jones EA, Cerny AM, Chan M, Bronson RT, Finberg RW. 2009. MyD88 intrinsically regulates CD4 T-cell responses. J. Virol. 83: 1625-1634. http://dx.doi.org/10.1128/JVI.01770-08.
77. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R. 2011. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 19:150-158. http://dx.doi.org/10.1038/mt.2010.225.
78. Li J, Faber M, Dietzschold B, Hooper DC. 2011. The role of toll-like receptors in the induction of immune responses during rabies virus infection. Adv. Virus Res. 79:115-126. http://dx.doi.org/10.1016/B978-0-12-387040-7.00007-X.
79. Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H, Chaplin P, Suter M, O'Keeffe M, Hochrein H. 2008. Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118:1776-1784. http://dx.doi.org/10.1172/JCI33940.